1. Home
  2. FOR vs DMRA Comparison

FOR vs DMRA Comparison

Compare FOR & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forestar Group Inc

FOR

Forestar Group Inc

HOLD

Current Price

$28.36

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$28.86

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FOR
DMRA
Founded
2005
2011
Country
United States
United States
Employees
N/A
7
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
FOR
DMRA
Price
$28.36
$28.86
Analyst Decision
Buy
Buy
Analyst Count
3
2
Target Price
$32.67
$43.00
AVG Volume (30 Days)
151.7K
841.0K
Earning Date
04-21-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.63
N/A
Revenue
$1,662,400,000.00
N/A
Revenue This Year
$0.34
N/A
Revenue Next Year
$7.73
N/A
P/E Ratio
$17.12
N/A
Revenue Growth
10.14
N/A
52 Week Low
$22.81
$16.50
52 Week High
$32.06
$34.89

Technical Indicators

Market Signals
Indicator
FOR
DMRA
Relative Strength Index (RSI) 43.58 53.60
Support Level $28.18 $22.71
Resistance Level $29.44 N/A
Average True Range (ATR) 1.03 2.72
MACD -0.40 -0.19
Stochastic Oscillator 43.38 35.35

Price Performance

Historical Comparison
FOR
DMRA

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: